Clinical observation of pediatric Tuina as an auxiliary therapy for refractory mycoplasma pneumoniae pneumonia in children

XIAO Yu-yao; WANG Mei; MAN Li-na; SUI Zheng

doi:10.16048/j.issn.2095-5561.2024.03.07

Abstract：Objective To evaluate the effectiveness and safety of pediatric Tuina as an auxiliary therapy for refractory mycoplasma pneumoniae pneumonia(RMPP) in children.Methods A total of 73 patients with RMPP admitted from January 2023 to January 2024 were selected as the study subjects.According to the random number table method,they were divided into two groups,combination treatment group( n=36) and azithromycin treatment group( n=37) .All patients received azithromycin treatment and adjuvant therapy.On this basis,the combination treatment group was administered Tuina therapy aimed at clearing heat,benefiting the lungs,and relieving cough.Some parameters such as the traditional Chinese medicine syndrome scores,time for major symptoms to subside,laboratory-test indicators,treatment efficacy,adverse reactions were compared between two groups.Results The total score of traditional Chinese medicine syndrome,main syndrome score,and secondary syndrome score of the two groups after treatment were significantly reduced than the scores of the two groups before treatment,and the differences were statistically significant( P<0.05) .After treatment,the total score,main symptom score,and secondary symptom score of the combination treatment group were all lower than those of the azithromycin treatment group,and the differences were statistically significant( P<0.05) .The levels of white blood cell count( WBC),C-reactive protein(CRP),lactate dehydrogenase(LDH),fibrinogen(FIB),and D-dimer(D-D) of the two groups after treatment were significantly reduced than those of the two groups before treatment,and the differences were statistically significant( P<0.05) .After treatment,the platelet count(PLT)in the combination treatment group was lower than that before treatment,and the difference was statistically significant(P<0.05).After treatment,the PLT count,CRP,LDH,FIB,and D-D in the combined treatment group were lower than those in the azithromycin treatment group,and the differences were statistically significant( P<0.05) .The time of cough disappearance,fever resolution and lung rale disappearance in the combination treatment group were shorter than those in the azithromycin treatment group,and the differences were statistically significant( P<0.05) .After 14 days of treatment,the total effective rates of treatment of the two groups both reached 100.0％.The effect and recovery rate of azithromycin treatment group was 78.4％(29/37),which was significantly lower than that of combined treatment group[94.4％(34/36)],and the difference was statistically significant(P<0.05).During the treatment period,no serious adverse reactions were observed in the both groups.The incidence rates of nausea and vomiting,abdominal pain and diarrhea,and rash in the azithromycin treatment group were 37.8％( 14/37),27.0％( 10/37) and 35.1％( 13/37),respectively,which were higher than those in the combined treatment group[16.7％( 6/36)],[8.3％( 3/36)]and[11.1％(4/36)],the difference was statistically significant(P<0.05).Conclusion Pediatric Tuina has an auxiliary therapeutic effect on children RMPP,with fewer adverse reactions.